ArQule, Inc. to Present at Lazard Healthcare Conference

  ArQule, Inc. to Present at Lazard Healthcare Conference

Business Wire

WOBURN, Mass. -- November 07, 2012

ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at
the Lazard Capital Markets 9^th Annual Healthcare Conference on Wednesday,
November 14, 2012 at 11:30 a.m. The presentation will be web cast and may be
accessed through the investor relations section of the Company’s website,

About ArQule

ArQule is a biotechnology company engaged in the research and development of
next-generation, small-molecule cancer therapeutics. The Company’s targeted,
broad-spectrum products and research programs are focused on key biological
processes that are central to human cancers. ArQule’s lead product, in Phase 2
and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective
inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline
consists of ARQ 621, designed to inhibit the Eg5 kinesin motor protein, and
ARQ 736, designed to inhibit the RAF kinases. ArQule’s current discovery
efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are
focused on the identification of novel kinase inhibitors that are potent,
selective and do not compete with ATP (adenosine triphosphate) for binding to
the kinase.


ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/
Corp. Communications
Press spacebar to pause and continue. Press esc to stop.